点击显示 收起
Department of Human Nutrition
University of Illinois at Chicago
Chicago, IL 60612
E-mail: reynolds{at}uic.edu
Department of Nutrition and Food Management
Oregon State University
Corvallis, OR 97331
E-mail: j.leklem{at}comcast.net
Dear Sir:
We found the recent article by Friso et al (1) potentially intriguing. An association between vitamin B-6 status and coronary artery disease (CAD) in humans has been discussed for decades, but to date there has been no satisfactory biochemical explanation for this association (see, for example, reference 2). In their study, Friso et al stated " ... we excluded subjects with conditions known to influence B-vitamin metabolism ..."; however, they included smokers and nonsmokers in both their CAD-free subjects and their CAD patients (see Table 1 in their article). Although they further stated that they performed multivariate logistic regression analyses that controlled for smoking and other indexes, such a regression analysis does not preclude an increasing percentage of smokers in each of the successive quartiles of pyridoxal-5'-phosphate (PLP) concentrations (see Figure 1 in their article). Because smoking is a well-documented determinant of PLP concentrations (3-6), we would have anticipated that the PLP data would also have been stratified by smoking load or that the incidence of smokers and nonsmokers would have been reported for each quartile in Figure 1. These data should be fairly easy for the authors to check.
In addition, more information on the intake of vitamin B-6 from the diet and from supplements needs to be provided. Moreover, because of the inverse association between circulating PLP concentrations and the activity of plasma alkaline phosphatase, the activity of alkaline phosphatase needs to be provided for both groups of subjects. After these analyses, if the associations of PLP with C-reactive protein and fibrinogen continue to hold up, then a functional role for vitamin B-6 in the prevention of CAD may finally be at hand.
REFERENCES